Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $66.29.
JANX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, May 9th. BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Jonestrading initiated coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Bank of America lifted their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Finally, Scotiabank initiated coverage on Janux Therapeutics in a research note on Thursday, May 30th. They issued a “sector perform” rating and a $47.00 price objective on the stock.
Check Out Our Latest Research Report on Janux Therapeutics
Insider Buying and Selling
Hedge Funds Weigh In On Janux Therapeutics
A number of institutional investors have recently made changes to their positions in JANX. Lord Abbett & CO. LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at approximately $20,420,000. RA Capital Management L.P. increased its holdings in shares of Janux Therapeutics by 5.7% in the 3rd quarter. RA Capital Management L.P. now owns 9,165,652 shares of the company’s stock valued at $92,390,000 after acquiring an additional 495,008 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Janux Therapeutics by 27.8% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $11,592,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at approximately $7,278,000. 75.39% of the stock is owned by institutional investors and hedge funds.
Janux Therapeutics Price Performance
JANX opened at $41.72 on Friday. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -34.20 and a beta of 3.58. The business has a 50-day moving average of $47.65 and a two-hundred day moving average of $32.38. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. Equities research analysts anticipate that Janux Therapeutics will post -1.34 earnings per share for the current year.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Articles
- Five stocks we like better than Janux Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Read Stock Charts for Beginners
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to invest in blue chip stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.